As per the deal, both the firms will work together for identifying and characterizing biomarkers for drug development, drug discovery and diagnostics applications for range of therapeutic areas.
The filing of the NDA is backed by the results from a multicenter, two-cohort, single-arm, open-label Phase II Erivance BCC study that investigated vismodegib in patients with advanced
Esbriet is an orally active drug that inhibits the synthesis of TGF-beta, a chemical mediator that controls many cell functions including proliferation and differentiation, and plays a key
Using its proprietary antibody discovery platforms, Humabs is focused on the discovery and development of next-generation fully human monoclonal antibodies targeted at infectious and inflammatory diseases. The technologies
The grant permits Diamyd to develop NTDDS-based drug candidate designed to deliver a neurotrophic factor to nerve cells. Neurotrophic factors are a class of small proteins which promote
Ceplene is administered with interleukin-2 (IL-2) for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first complete remission. The FDA indicated
Ark will work with PsiOxus in providing oncolytic adenoviral material for IV administration in toxicological and Phase I/II clinical studies, using Ark’s suspension based single use system (ATOSUS).
Silence is currently conducting a Phase I trial with Atu027 in patients with advanced solid cancer. Interim data analysis from this trial showed that Atu027 is safe and
Simponi is a human monoclonal antibody that targets and neutralizes excess TNF-alpha, a protein that when overproduced in the body due to chronic inflammatory diseases can cause inflammation
GDUFA requires the FDA to commit to significantly improve and enhance its regulatory activities for the benefit of global generic drug providers and US generic drug users, in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.